ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NSCI Netscientific Plc

53.50
0.00 (0.00%)
18 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific Plc LSE:NSCI London Ordinary Share GB00BN4R5Q82 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 53.50 53.00 54.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.45M -2.64M -0.1104 -4.85 12.81M
Netscientific Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NSCI. The last closing price for Netscientific was 53.50p. Over the last year, Netscientific shares have traded in a share price range of 53.50p to 77.00p.

Netscientific currently has 23,945,828 shares in issue. The market capitalisation of Netscientific is £12.81 million. Netscientific has a price to earnings ratio (PE ratio) of -4.85.

Netscientific Share Discussion Threads

Showing 5801 to 5819 of 6000 messages
Chat Pages: 240  239  238  237  236  235  234  233  232  231  230  229  Older
DateSubjectAuthorDiscuss
28/5/2024
07:15
Following various fundraisings and strategic changes to the Wanda business as detailed below, the NetScientific Directors believe that the Wanda business has now been materially de-risked, having made significant commercial and operational progress, underpinning significant growth prospects, placing it in a stronger position than in 2019. The Board is accordingly delighted for the Group to be in a position to re-acquire a strategic stake in Wanda, providing it with exposure to the fast-growing remote patient monitoring market. The Investment is in line with the Company's strategy of deepening stakes in selected portfolio companies with high return potential.
blakieboy7
28/5/2024
07:05
Another decent deal for NSCI.

Wanda on the books as 90% CUA valued at £3.6M. We have no direct holding.

We now have 30% direct holding so worth £1M+ (see above)

£150K upfront fee.

£100K a year management charge. (£8K month)

loafofbread
24/5/2024
08:58
When this share goes down on light volume it is mainly to do with MM's widening spread to 4 p. When it goes up the spread becomes tighter at 2p or less. You can say that there is actually no movement.
kingston78
21/5/2024
07:15
Interesting tweet/X out last night from Netscientific.

Charles Swindell is presenting at the Jefferies Health Care on June 4-6th, talking about Glycotest and ProAxis.

He runs Glycotest and he hasn't said or done anything for at least 5 years.

Is it safe to assume we will have some positive Glycotest news beforehand otherwise he won't have much to say other than talk about 4 years of delays!?

loafofbread
17/5/2024
12:29
Finally, a nice move up on the bid.
loafofbread
17/5/2024
12:25
That's better, now let's crack 70p and beyond
blakieboy7
16/5/2024
16:42
70,000 of straight buys today. That first 15k moved the offer up.

Interest slowly returning.

loafofbread
16/5/2024
13:38
In PDSB's 1Q 10-Q report, filed yesterday, you can see that they used their "at the market" sales agreement to sell 3.4m shares into the market at an average price of something like $5.70/share in 1Q. They raised $19.5m this way, which is great for their cash runway, but obviously acts as a headwind for the shareprice.

"During the quarter ended March 31, 2024 and 2023, the Company sold 3,428,681 and 553,293 shares of common stock for a net value of $19.5 and $4.6 million, respectively, pursuant to the Sales Agreement."




free stock charts from uk.advfn.com

1gw
16/5/2024
11:51
I hope that Fosan will bid for the whole of Glycotest. That will be a quantum leap for NSCI.
kingston78
16/5/2024
09:31
The MMs do love their delayed trades in NSCI!
loafofbread
15/5/2024
18:32
NAV is £44M vs £15M MCap

I think the risk/reward is as good as it gets.

Glycotest is valued in the books at £11M and we are finally close to a read out. Could be worth £5M or £50M if the test works and Fosan want full control.

ProAxis worth £8M. since then received another £500K in funding grants. Might go for £10M/£15M with a fair wind.

Downside fully protected but upside is potentially massive.

loafofbread
14/5/2024
12:21
Vox interview much better than yesterdays Proactive effort.

Clear explanation of what's to come and how this is a win win for NSCI shareholders.

loafofbread
14/5/2024
09:49
So much going on but nothing being reflected in the share price!
blakieboy7
14/5/2024
09:31
NetScientific Q&A: "we're right in the middle of the action of venture capital"
sev22
13/5/2024
21:13
hTtps://stkt.co/Z4P0GIZh PDSB presentation a few hours ago
blakieboy7
13/5/2024
19:37
Today's news was hugely significant I suspect we will kick on from here in my opinion
senttothegallows
13/5/2024
18:49
Could also do with some Simon Thompson PR
blakieboy7
13/5/2024
10:35
great points.
think results are due imminently - perhaps there'll be some positive narrative to expand on the recent raft of good news which stirs up the wider markets.

mortimer7
13/5/2024
10:18
Yet again completely ignored by the wider market.

M7, I think the ProAxis value uplift from £3.5M to £8M+ might have had you opening that drawer a few weeks ago.

They won another £500K grant last week.

The sooner the company starts a share buy back to narrow the discount to NAV the better.

Once they have closed the gap somewhat they can invest elsewhere!

loafofbread
Chat Pages: 240  239  238  237  236  235  234  233  232  231  230  229  Older